Immunovant Reports Q1 Results for Quarter Ended June 30, 2026

What Happened

• Immunovant, Inc. filed a Form 8-K on August 6, 2026 to report its results of operations and financial condition for the fiscal first quarter ended June 30, 2026.
• The company issued a press release announcing the quarterly results; that press release is furnished as Exhibit 99.1 to the Form 8-K.
• The filing was signed by Chief Financial Officer Tiago Girao on August 6, 2026.

Key Details

• Event type: Results of operations / financial condition disclosure (Item 2.02).
• Press release date: August 6, 2026 (Exhibit 99.1).
• Reporting period: Fiscal first quarter ended June 30, 2026.
• Form 8-K signed by: Tiago Girao, Chief Financial Officer.

Why It Matters

• This 8-K publicly discloses Immunovant’s latest quarterly results (earnings and revenue-related information will be in the press release). Investors should review Exhibit 99.1 for the company’s reported revenue, net income (or loss), cash position, and any commentary on guidance or business drivers.
• Because the information was furnished on Form 8-K, the quarterly results are now immediately available to the market; traders and long-term investors may want to read the press release before making decisions.